MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 300165 | Name: Desmopressin acetate trihydrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desmopressin (DDAVP) is a synthetic analog of vasopressin with enhanced antidiuretic activity and reduced vasopressor effects. It selectively binds to the vasopressin V2 receptor (V2R) in the renal collecting ducts, stimulating aquaporin-2 (AQP2) translocation to the apical membrane, leading to increased water reabsorption and reduced urine output. Desmopressin exhibits a high affinity for V2R (Ki ~0.3 nM) and minimal activity at V1 receptors, lowering its hypertensive risk. Clinically, it is used for central diabetes insipidus, nocturnal enuresis, and mild hemophilia A by increasing plasma levels of factor VIII and von Willebrand factor. Pharmacokinetically, desmopressin has an elimination half-life of ~2–4 hours when administered intranasally or intravenously and shows bioavailability of ~0.08% (oral) and ~3–5% (intranasal).

Chemical Structure

Desmopressin acetate trihydrate
Desmopressin acetate trihydrate
CAS#62357-86-2 (acetate trihydrate)

Theoretical Analysis

MedKoo Cat#: 300165

Name: Desmopressin acetate trihydrate

CAS#: 62357-86-2 (acetate trihydrate)

Chemical Formula: C48H74N14O17S2

Exact Mass: 0.0000

Molecular Weight: 1189.32

Elemental Analysis: C, 48.72; H, 6.30; N, 16.57; O, 22.99; S, 5.42

Price and Availability

Size Price Availability Quantity
1mg USD 90.00 Ready to Ship
5mg USD 150.00 Ready to Ship
10mg USD 250.00 Ready to Ship
25mg USD 450.00 Ready to Ship
50mg USD 750.00 Ready to Ship
100mg USD 1,250.00 Ready to Ship
1g USD 4,650.00 Ready to Ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
62357-86-2 (acetate trihydrate) 69-25-0 (free base) 62288-83-9 (acetate) 16679-58-6 (free base)
Synonym
Adiuretin; Deamino Arginine Vasopressin; Desmogalen; Vasopressin 1-Desamino-8-arginine; trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate; Nocutil. Pubchem ID64759
IUPAC/Chemical Name
(S)-1-((4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-((R)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)pyrrolidine-2-carboxamide acetate trihydrate
InChi Key
YNKFCNRZZPFMEX-XHPDKPNGSA-N
InChi Code
InChI=1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2/t28-,29+,30+,31+,32+,33+,34+;;;;/m1..../s1
SMILES Code
O=C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSCCC4=O)=O)CCC1)N[C@H](CCCNC(N)=N)C(NCC(N)=O)=O.CC(O)=O.[H]O[H].[H]O[H].[H]O[H]
Appearance
white to light yellow crystal
Purity
>99% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water or DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 62357-86-2 (Desmopressin acetate trihydrate); 62288-83-9 (Desmopressin acetate); 16679-58-6 (Desmopressin free base); 16789-98-3 (Desmopressin diacetate). Note: The drug API approved by FDA is Desmopressin acetate trihydrate, which CAS# is 62357-86-2 with Chemical Formula: C48H74N14O17S2 and Molecular Weight: 1183.31. Other forms of Desmopressin: Desmopressin (not FDA approved drug API) CAS# 16679-58-6 (desmopressin); Chemical Formula: C47H64N12O13S2 Exact Mass: 1068.41572; Molecular Weight: 1069.21 Elemental Analysis: C, 52.80; H, 6.03; N, 15.72; O, 19.45; S, 6.00 Desmopressin Acetate (not FDA approved drug API) CAS#62288-83-9 (desmopressin acetate); Chemical Formula: C49H68N12O15S2 Molecular Weight: 1129.26 Elemental Analysis: C, 52.12; H, 6.07; N, 14.88; O, 21.25; S, 5.68 Desmopressin diacetate (not FDA approved drug API) CAS#16789-98-3 (desmopressin diacetate) Chemical Formula: C50H72N14O16S2; Molecular Weight: 1189.32 Elemental Analysis: C, 50.49; H, 6.10; N, 16.49; O, 21.52; S, 5.39 Mode of action: Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor. Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension. [source: http://en.wikipedia.org/wiki/Desmopressin]. INDICATIONS: Central Diabetes Insipidus: DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. [source: http://www.rxlist.com/ddavp-drug.htm].
Solvent mg/mL mM
Solubility
Soluble in in water 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,189.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Malve H, Goswami P, Asalkar A, More D. Role of Desmopressin in Bleeding Disorders: What Indian Physicians Need to Know? J Assoc Physicians India. 2025 Jan;73(1):58-60. doi: 10.59556/japi.73.0796. PMID: 39893530. 2: Kim SH, Bae AY, Kim DH, Hwang SH. Does Desmopressin Reduce Intraoperative Bleeding in Patients Who Undergo Nasal Surgery? A Systematic Review and Meta- Analysis. J Rhinol. 2024 Mar;31(1):8-16. doi: 10.18787/jr.2024.00007. Epub 2024 Mar 31. PMID: 39664036; PMCID: PMC11566543. 3: Everaert K, Holm-Larsen T, Bou Kheir G, Rottey S, Weiss JP, Vande Walle J, Kabarriti AE, Dossche L, Hervé F, Spinoit AF, Nørgaard JP, Juul KV. Potential clinical applications of current and future oral forms of desmopressin (Review). Exp Ther Med. 2024 May 29;28(2):303. doi: 10.3892/etm.2024.12592. PMID: 38873038; PMCID: PMC11170333. 4: Shahzad F, Ahmed U, Muhammad A, Shahzad F, Naufil SI, Sukkari MW, Kamran AB, Murtaza S, Khalid MB, Shabbir H, Saeed S. Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and metaanalysis. Brain Behav. 2024 May;14(5):e3540. doi: 10.1002/brb3.3540. PMID: 38778788; PMCID: PMC11112402. 5: Giampietro RR, Cabral MVG, Pereira EG, Machado MC, Vilar L, Nunes-Nogueira VDS. Accuracy of the 10 μg desmopressin test for differential diagnosis of Cushing syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024 Jan 30;15:1332120. doi: 10.3389/fendo.2024.1332120. PMID: 38352712; PMCID: PMC10861662. 6: Wang C, Lebedeva V, Yang J, Anih J, Park LJ, Paczkowski F, Roshanov PS. Desmopressin to reduce periprocedural bleeding and transfusion: a systematic review and meta-analysis. Perioper Med (Lond). 2024 Jan 23;13(1):5. doi: 10.1186/s13741-023-00358-4. PMID: 38263259; PMCID: PMC10804695. 7: Cai T, Yao Y, Sun W, Lei P. Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta- analysis. Front Pediatr. 2023 Oct 19;11:1242777. doi: 10.3389/fped.2023.1242777. PMID: 37928358; PMCID: PMC10620680. 8: Tang G, Liu H, Wu G, Ding G, Chu Y, Cui Y, Wu J. The pooled analysis evaluates the therapeutic efficacy of desmopressin combined with anticholinergic drugs in the treatment of pediatric nocturnal enuresis. Neurourol Urodyn. 2024 Jan;43(1):183-195. doi: 10.1002/nau.25295. Epub 2023 Oct 3. PMID: 37787540. 9: Jinnouchi T, Yoshimoto M, Ogino K, Oji T, Hayashi M. Lithium-induced Nephrogenic Diabetes Insipidus with Efficacy of Desmopressin in Combination with Thiazide Diuretics and Non-steroidal Anti-inflammatory Drugs: A Case Report with a Review of the Literature. Intern Med. 2024 May 15;63(10):1399-1404. doi: 10.2169/internalmedicine.2437-23. Epub 2023 Sep 29. PMID: 37779064; PMCID: PMC11157307. 10: Al Arashi W, Romano LGR, Leebeek FWG, Kruip MJHA, van Galen KPM, Turan O, Kadir RA, Cnossen MH; SYMPHONY consortium. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder: a systematic literature review. J Thromb Haemost. 2024 Jan;22(1):126-139. doi: 10.1016/j.jtha.2023.09.021. Epub 2023 Sep 30. PMID: 37778511. 11: Hajebrahimi S, Darvishi A, HajEbrahimi R, Asadi N, Jafari Shendi Z, Asiaban N, Naseri A, Sadeghi-Ghyassi F, Mostafaei H, Salehi-Pourmehr H. Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta-analysis. Neurourol Urodyn. 2024 Jan;43(1):167-182. doi: 10.1002/nau.25291. Epub 2023 Sep 25. PMID: 37746880. 12: Beltran A, Jaramillo AP, Vallejo MP, Acosta L, Barberan Parraga GC, Guanín Cabrera CL, Gaibor VG, Cueva MG. Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review. Cureus. 2023 Aug 29;15(8):e44310. doi: 10.7759/cureus.44310. PMID: 37649925; PMCID: PMC10464544. 13: Jahangirifard A, Mirtajani SB, Madadi F. Effect of Desmopressin on Bleeding After Heart Surgeries: A Narrative Review. Anesth Pain Med. 2023 Mar 10;13(2):e133894. doi: 10.5812/aapm-133894. PMID: 37645010; PMCID: PMC10461384. 14: Mohinani A, Patel S, Tan V, Kartika T, Olson S, DeLoughery TG, Shatzel J. Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12. PMID: 36656570; PMCID: PMC10073345. 15: Alrajhi AA, Alghamdi AS, Baali MH, Altowairqi AF, Khan MF, Alharthi AS, Albazee E, Abu-Zaid A. Efficacy of prophylactic pre-operative desmopressin administration during functional endoscopic sinus surgery for chronic rhinosinusitis: A systematic review and meta-analysis of randomised placebo- controlled trials. Clin Otolaryngol. 2023 Mar;48(2):139-150. doi: 10.1111/coa.14020. Epub 2023 Jan 3. PMID: 36536598. 16: Castinetti F, Lacroix A. Is Desmopressin Useful in the Evaluation of Cushing Syndrome? J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4295-e4301. doi: 10.1210/clinem/dgac533. PMID: 36103267. 17: Hwang EC, Jung HJ, Han MA, Kim MH, Yu SH, Jeong HC, Kim JS, Paick SH, Yeo JK, Jung JH; Korean Urological Association Guideline Development Committee. Korean guideline of desmopressin for the treatment of nocturia in men. Investig Clin Urol. 2022 Sep;63(5):499-513. doi: 10.4111/icu.20220165. PMID: 36067995; PMCID: PMC9448671. 18: Valizadeh M, Ahmadi AR, Ebadinejad A, Rahmani F, Abiri B. Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. Rev Endocr Metab Disord. 2022 Oct;23(5):881-892. doi: 10.1007/s11154-022-09723-y. Epub 2022 Apr 28. PMID: 35478451. 19: Virú-Loza MA, Quispe AV. Diagnostic Power of Bilateral Inferior Petrosal Sinus Sampling with Desmopressin in Paediatric Cushing’s Disease. J Clin Res Pediatr Endocrinol. 2022 Aug 25;14(3):334-338. doi: 10.4274/jcrpe.galenos.2022.2022-12-9. Epub 2022 Mar 21. PMID: 35308013; PMCID: PMC9422914. 20: Sreeraman S, McKinlay S, Li A, Crowther M, Motalo O. Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review. Thromb Res. 2022 May;213:16-26. doi: 10.1016/j.thromres.2022.02.019. Epub 2022 Feb 26. PMID: 35278886.